– USA, NY – Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr. Enoch Kariuki, PharmD, to its Board of Directors. ... President and Director of Zentalis Pharmaceuticals. NEW YORK & SAN DIEGO – Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, … About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis’ Scientific Advisory Board See the breakdown of the total annual compensation for David M. Johnson for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC “We are excited to welcome David to our board as he brings his … Zentalis Pharmaceuticals is a New York City and San Diego based biotech company dedicated to the discovery and development of clinically differentiated small molecules targeting fundamental biological pathways of cancer. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. “We are pleased to welcome Enoch to our Board of Directors, and believe his...--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical … Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, ... 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. Please contact us at bd@ null zentalis.com to discuss partnering and collaborations opportunities. Anthony has played an active role across the life science industry since 2002 and currently serves as President and Chief Executive Officer for Zentalis Pharmaceuticals. Name Total COMPENSATION; Cam S. Gallagher: Total Cash $3,339,132: David M. Johnson: Board of Directors in Zentalis Pharmaceuticals, Inc. For its 2020 fiscal year, Zentalis Pharmaceuticals, Inc., listed the following board members on its annual proxy statement to the SEC. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The Board of Directors of Zentalis Pharmaceuticals. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support The Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) has adopted the following Corporate Governance Guidelines (the “Guidelines”) to assist the Board in the exercise of its responsibilities and to serve the interests of the Company and its stockholders. Mr. – USA, NY – Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. post or otherwise publish any content unrelated to the board or the board's topic. Search Jobs; Connect With Us; Partners. He will report to Chief Executive Officer Dr. Kimberly Blackwell. Johnson is a veteran … Zentalis provides equal employment opportunity to all employees and applicants without regard to an individual’s protected status. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors /EIN News/ -- NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological … View detailed ZNTL.US description & address. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. NEW YORK & SAN DIEGO-- ( BUSINESS WIRE )-- Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Dr. Blackwell is a renowned breast cancer … Corporate Governance Overview. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 5.02. – USA, NY – Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors. NEW YORK & SAN DIEGO – Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors.Mr. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. In addition, Board member Dave Johnson has been appointed Chairman. re-post premium share chat posts on regular share chat. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. 1-212-433-3791 info@zentalis.com ... Dr. Blackwell has been an independent director of Zentalis since 2020. 357th out of 679 stocks Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Company’s founding. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. “We are pleased to welcome Enoch to our Board of Directors, and believe his...--Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical … Dr Wollowick is the Sr. Director of Business… Liked by Yelena Lalazar (Blumshtein) I was 17 years old when I was forced into an arranged marriage. – USA, NY – Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Dr Kimberly Blackwell to its Board of Directors. Implicit in this philosophy is the importance of sound corporate governance. Zentalis intends to use the net proceeds of the offering to help fund ongoing and planned clinical trials, including studies of ZN-c3, its Wee1 inhibitor, and ZN-d5, its BCL-2 inhibitor, and for working capital and general corporate purposes. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Gallagher, who previously served as an Executive Director of Zentalis, will remain a member of the Board of Directors, which he has served on since the Company’s founding. (the "Company") sets high standards for the Company's employees, officers and directors. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors On June 30, 2022, the Board of Directors (the "Board") of BioXcel Therapeutics, Inc. (the "Company") appointed Michael Miller to the Board, ... 65, has served as an advisor to pharmaceutical companies, Zentalis Pharmaceuticals, Inc. and Protagonist Therapeutics, Inc., since July 2021 and September 2020, respectively. Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors. I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years.” Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. The AP news staff was not involved in its creation. Non-employee members of the board of directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”).This Program has been adopted under the Company’s 2020 Incentive Award Plan (the “Equity Plan”) and shall be … NEW YORK and SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological … Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. The Pfizer Board Policies Ensuring ethical leadership Corporate Governance FAQs Learn more about our approach Contact Our Directors Email any of our Directors History; Careers. ... President and Director of Zentalis Pharmaceuticals. Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board. Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors. ” Melissa Epperly has served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage cancer company, since September 2019. Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors Explore New York business news Jan 9 2020 BoardMoves Mr. Johnson is a veteran biopharmaceutical and healthcare leader with more than 25 years of experience in developing drugs and … Download PDF. On May 25, 2022, the Board of Directors (the "Board") of Zentalis Pharmaceuticals, Inc. (the "Company") appointed Cam S. Gallagher, a current Executive Director of the Company and a current member of the Board, as President of the Company, succeeding Kimberly Blackwell in such role, effective as of May 30, 2022 (the "Commencement Date"). On May 10, 2022,... | July 3, 2022 Dr. 734th out of 1,418 stocks. I would like to thank Pat Machado for his contributions to the Board and Roivant over the past six years . – USA, NY – Zentalis Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Learn about the executive team and board of directors at Zentalis Pharmaceuticals Inc Ordinary Shares (ZNTL:XNAS) and review their bios and compensation over the latest fiscal years. Matricelf is happy to announce that Adam Wollowick MD/MBA is joining its scientific advisory board. She brings extensive experience as a senior financial executive in the life sciences industry. Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Research and Business Development Partnerships ... Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer. Sun, M.D., has served as the Company’s President and Chief Executive Officer and Chairman of the Company’s Board of Directors since December 2014. Science Center. Posted on 07/01/2020 72 . 1-212-433-3791 info@zentalis.com Zentalis Pharmaceuticals Appoints David Johnson to Board of Directors. Pharmaceutical Preparations Industry. On May 10, 2022,... | July 3, 2022 restrict or inhibit any other user from using the boards. Investors/Media Home Company Profile. About Zentalis We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Michelle Arthur Associate Director Pharmacovigilance at Zentalis Pharmaceuticals Somerville, New Jersey, United States 298 connections 10835 Road to the Cure Suite 205 San Diego, CA 92121. Company profile for Zentalis Pharmaceuticals Inc. including key executives, insider trading, ownership, revenue and average growth rates. The Board of Directors of Zentalis Pharmaceuticals. For More Information. Dr. Blackwell is a current member of Zentalis’ Board and previously served as Chief Medical Officer of Tempus Labs and held clinical development leadership roles at Eli Lilly and Company. Zentalis Pharmaceuticals (the “Company” or “Zentalis”), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways in cancer, today announced the appointment of David Johnson to its Board of Directors. Implicit in this philosophy is the importance of sound corporate governance. Board members at this company Cam S. Gallagher David M. Johnson Kimberly Blackwell As a member of Board of Directors at Zentalis Pharmaceuticals, Inc. , Cam S. Gallagher made $3,339,132 in total compensation. Press release content from Business Wire. (the "Company") sets high standards for the Company's employees, officers and directors. He will report to Chief Executive Officer Dr. Kimberly Blackwell. Jan 9, 2020 at 8:00 AM EST. Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. Non-employee members of the board of directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective March 18, 2021 (the “Effective Date”).This Program has been adopted under the Company’s 2020 … 10275 Science Center Drive Suite 200 San Diego, CA 92121 Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Notice to Search Firms/Third-Party Recruitment Agencies (Recruiters) The Human Resources team manages the recruitment and employment process for Zentalis Pharmaceuticals, Inc. (Zentalis) To protect the interest of all parties involved, Zentalis will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort. For More Information. She brings extensive experience as a senior financial executive in the life sciences industry. 10835 Road to the Cure Suite 205 San Diego, CA 92121. The average salary for Director of Philanthropy at companies like ZENTALIS PHARMACEUTICALS INC in the United States is $169,600 as of April 26, 2022, but the range typically falls between $144,400 and $199,700. See the breakdown of the total annual compensation for Kimberly Blackwell for being a board member of ZENTALIS PHARMACEUTICALS INC, as well as other members of the Board of Directors for ZENTALIS PHARMACEUTICALS INC Medical Sector. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of … On June 21, 2022, Alexis M. Pinto notified Zentalis Pharmaceuticals, Inc. (the "Company") of her resignation as Chief Legal Officer and Secretary of the Company, effective as of July 5, 2022. Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells Adam Schayowitz, Ph.D., MBA, Vice President & Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma, Pfizer, to join Zentalis’ Scientific Advisory Board Previously, she held increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of vice president of legal. “We are excited to welcome David to our board as he brings his … Sun serves as Chief Executive Officer and a member of the board of directors of Zentera, the Company’s joint venture in China and Kalyra Pharmaceuticals, Inc., or Kalyra, a small molecule drug discovery and … Anthony Y. Item 5.02. Before Zentalis, Paul served as general counsel and corporate secretary at LogicBio Therapeutics, Inc. January 09, 2020 08:00 AM Eastern Standard Time. Item 5.02. Dr. Kariuki is a highly accomplished finance …